Merck & Co., Inc. Deferred Other Tax Expense (Benefit)
Merck & Co., Inc. (MRK) reported Deferred Other Tax Expense (Benefit) of $75.00 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredOtherTaxExpenseBenefit · last filed 2016-11-07
- Merck & Co., Inc. deferred other tax expense (benefit) for the quarter ending 2015-09-30 was $0.00.
- Merck & Co., Inc. deferred other tax expense (benefit) for the quarter ending 2015-06-30 was $75.00M.
| Period end | Deferred Other Tax Expense (Benefit) 3 month | Deferred Other Tax Expense (Benefit) 6 month | Deferred Other Tax Expense (Benefit) 6 month as first filed | Deferred Other Tax Expense (Benefit) 9 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $75.00M derived: sum of 2 quarters · filed 2016-11-07 | $75.00M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $75.00M 10-Q · filed 2016-08-08 | $75.00M 10-Q · filed 2016-08-08 | -$75.00M 10-Q · filed 2015-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |